As gedatolisib is a potent pre-clinical anticancer target drug, the evaluation of ABC transporters excluded ABCB1 and ABCG2 is urgently to be further investigated in the further, which will make better understanding the mechanisms of action on gedatolisib resistance in CRC. Here, ABCG2 is linked to colorectal carcinoma.